Mineralocorticoid Receptor Antagonist Discontinuation in Adrenal Venous Sampling for Subtyping Patients With Primary Hyperaldosteronism: A Systematic Review and Meta‐Analysis
Pooled resultResult — go to the resultOR for lateralization consistent with unilateral disease 2.1 95% CI 1.4–3.1Authors' conclusion
Concurrent use of MRA treatment did not adversely affect the diagnostic performance of AVS, rates of PA lateralization or postoperative outcomes.
Study context
- Population
- Patients with primary aldosteronism (PA) who underwent adrenal venous sampling (AVS) while on or off concurrent mineralocorticoid receptor antagonist (MRA) treatment
- Participants
- 1,116 patients4 retrospective cohort studies
- Comparison
- Continued vs discontinued MRA during AVS
- MRAn = 147
- Outcome
- AVS success and lateralization
Methodological detailsfive databases searched, no time restrictions
- Five databases searched
- No time restrictions
Pooled result
As reported in the abstract
OR for lateralization consistent with unilateral disease
2.1
95% CI 1.4–3.1
By group
MRA continuedvs MRA discontinued
OR for lateralization consistent with unilateral disease 2.1 (95% CI 1.4–3.1)
Further pooled results
Postoperative clinical success
- Clinical success rates comparable between MRA and non-MRA groups
Postoperative biochemical success
- Biochemical success rates comparable between MRA and non-MRA groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Mineralocorticoid Receptor Antagonist Discontinuation in Adrenal Venous Sampling for Subtyping Patients With Primary Hyperaldosteronism: A Systematic Review and Meta‐Analysis. Clin Endocrinol (Oxf). Published 10 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →